The Introduction of Sigma Receptors {#sec1}
===================================

Sigma Receptors {#sec2}
---------------

Sigma receptors were mistakenly categorized as one kind of the opioid receptors because they had high-affinity binding sites for SKF-10047, which is a classic opioid receptor ligand ([@ref56]; [@ref114]). Later, researchers realized that they were totally different receptors ([@ref56]; [@ref114]). Sigma receptors are abundant in the central nervous system (CNS); they are expressed in the hippocampus, cerebellum, basal ganglia, and spinal cord ([@ref14]; [@ref104]). Two Sigma receptor subtypes, Sigma-1 receptor and Sigma-2 receptor, have been identified according to their different binding profiles and molecule weights ([@ref89]). While the Sigma-1 receptor was cloned many years ago, the identity of Sigma-2 receptor still remains uncertain, although several candidates have been proposed ([@ref95]). In recent years, significant progress has been made in our understanding of roles of the Sigma-1 receptors in normal and pathological conditions, but more studies are still required for the Sigma-2 receptor due to the lack of suitable research tools ([@ref56]; [@ref114]). It is well accepted that Sigma receptors are non-G protein-coupled receptors (non-GPCRs); they are intracellular chaperone proteins ([@ref89]). They can bind many unrelated and structurally diverse ligands and are involved in many cellular functions. Sigma-1 receptor plays very important roles in many CNS diseases such as Major Depressive Disorder (MDD), Parkinson's disease (PD), and Alzheimer's disease (AD) ([@ref89]). Whereas Sigma-2 receptor is involved in cancers and AD, Sigma-2 receptor antagonists block the memory impairments in AD ([@ref1]).

Sigma receptors localize mainly at the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) ([@ref37]) and in some plasma membranes (PM) ([@ref64]; [@ref63]). Upon stimulation, Sigma receptors translocate from the MAM to the PM, where Sigma receptors interact with many receptors and ion channels ([@ref114]). Sigma receptor might also move from the MAM to the nucleus membrane to interact with nucleus factors and regulate gene transcription ([@ref118]).

### Sigma-1 Receptor {#sec3}

The Sigma-1 receptor shares no amino acid sequence homology with any other mammalian proteins. However, it has 60% amino acid identity to an enzyme, ERG2, which is required for sterol synthesis in yeast, whereas the Sigma-1 receptor does not have any enzyme activity ([@ref56]; [@ref114]). The interaction between Sigma-1 receptor and sterol has been well studied, and several sterols and lipids could act as endogenous ligands for Sigma-1 receptor. For these interactions, tyrosine residues in Sigma-1 receptors are required ([@ref87]).

Hydrophobicity analysis has indicated that Sigma-1 receptor has two transmembrane domains, including amino acid (AA) sequence 11--29 and 92--112, which are named the transmembrane domain I (TMDI) and transmembrane domain II (TMDII), respectively. It is proposed that AA 29--92 forms a cytosolic loop and both the C- and N-termini are localized in the ER lumen ([@ref114]). In contrast to this two-pass transmembrane model, a recent study has revealed that Sigma-1 receptor has a single transmembrane topology, AA 6--31 comprises the single transmembrane helix, while AA 32--223 forms a C-terminal domain which is located in the cytosol. This domain includes a β-barrel and two flanking α-helices. Both the ligand-binding site and the oligomerization interface lie in this domain ([@ref101]).

### Sigma-2 Receptor {#sec4}

Up now, the molecular identity of Sigma-2 receptor has long been pursued. In 2006, Colabufo et al. proposed that Sigma-2 receptors are histone proteins since specific Sigma-2 ligand PB28 could pull down histone proteins ([@ref19]). However, later studies discarded this conclusion.

Sigma-2 receptor is also suggested as a component of the progesterone receptor membrane component 1 (PGRMC1) complex ([@ref126]). It is involved in cholesterol synthesis. Later, many articles were published to support this conclusion ([@ref46],[@ref47]; [@ref130]). However, this hypothesis had some serious drawbacks. For instance, the molecular size of PGRMC1 is different from that of the Sigma-2 receptor ([@ref42]). In addition, the Sigma-2 receptor could still be photoaffinity-labeled in the cells without PGRMC1 ([@ref18]; [@ref1]).

Recently, transmembrane protein 97 (TMEM97) was thought to have the same identity as the Sigma-2 receptor. TMEM97 is located in the ER and has the ability to regulate the sterol transporter Niemann-Pick disease, type C1 Protein (NPC1) ([@ref2]). In that study, the authors found that its pharmacologic profile is the same as that of Sigma-2 receptor; moreover, TMEM97 ligands bind Sigma-2 receptors ([@ref3]). A new study has also shown that Sigma-2 receptor/TMEM97 is involved in alcohol withdrawal behaviors, indicating that this receptor can be targeted to treat alcohol use disorder ([@ref103]).

These inconsistent studies leave the identity of Sigma-2 receptor open to debate. Over the years, many papers have shown that Sigma-2 receptor might be a promising target for AD and cancer. However, its unknown molecular identity has hindered further study. In addition, we still don't know its 3D structure. Although Sigma-2 receptor shares some pharmacological properties with Sigma-1 receptor, these two proteins have different roles in the CNS. This review will focus on Sigma-1 receptor.

### The Oligomerization of Sigma Receptor {#sec5}

Up to now, all the studies about oligomerization of Sigma receptors lie on Sigma-1. It is well known that Sigma-1 receptor could interact with itself and form oligomers ([@ref32]; [@ref68]). In one study, several high-molecular weight bands representing oligomers of Sigma-1 receptor appeared in rat liver membrane ([@ref86]). A broad range of oligomerization states of Sigma-1 receptor was also revealed using SEC-MALS (size-exclusion chromatography with multi-angle light scattering) and PAGE (native polyacrylamide gel electrophoresis) ([@ref101]). In addition, X-ray crystallization showed that human Sigma-1 receptor existed as a trimer with a transmembrane domain and a ligand binding site in each protomer ([@ref101]). A GXXXG motif of the Sigma-1 receptor is required for its oligomerization, since mutations within this region reduced its higher states of oligomerization while increased smaller oligomeric states ([@ref32]). These mutations also prevented ligand binding ([@ref32]).

Since Sigma-1 receptor could form a range of different oligomeric states, it is not surprising that different agonists and antagonists of Sigma-1 receptor induce distinct cellular effects through its distinct oligomeric states ([@ref68]; [@ref129]). A cell-based study using fluorescence resonance energy transfer (FRET) method showed that under non-liganded condition, Sigma-1 receptors form several different oligomeric states. When Sigma-1 receptors bind to their agonists or antagonists, antagonist favored higher order oligomer of receptors, while agonist enhanced the formation of small oligomers ([Figure 1](#fig1){ref-type="fig"}; [@ref68]). Consistently, in a non-denaturing gel assay, Sigma-1 receptor antagonist haloperidol promoted higher order oligomerization while agonist pentazocine favored its monomer and dimer states ([@ref129]).

![Sigma-1 receptor could form a range of different oligomeric states. While antagonist stabilized higher order oligomers, agonist instead favored small oligomers.](fphar-10-00528-g001){#fig1}

The promising hypothesis is that Sigma-1 receptor oligomerization states might affect its ability to bind client proteins including ion channels and BiP. For example, the preincubation of Sigma-1 receptor with ligands reduced the binding of Sigma-1 receptor monomer with the Nav 1.5 channel ([@ref5]). It is proposed that Sigma-1 receptor ligands including haloperidol and pentazocine could stabilize higher oligomeric (includes dimeric) states of the receptors, so less receptor monomers are available for the binding of Nav 1.5 channel. In addition, the conversion of oligomeric states of the receptor to its monomer might enhance its binding ability to client protein including BiP, since more C-terminus of the receptor was exposed in monomer. A recent correlation experiment showed that haloperidol which promoted the homomerization of the Sigma-1 receptor reduced Sigma-1 receptor-BiP interaction, whereas pentazocine which favored the production of monomers enhanced the interaction between Sigma-1 receptor and BiP ([@ref129]).

Signal Pathways Induced by the Activation of Sigma Receptors {#sec6}
------------------------------------------------------------

The activation of Sigma-1 receptors could induce several signaling pathways in cells ([@ref114]). It modulates Ca^2+^ signaling *via* the inositol triphosphate (IP~3~) receptor between the ER and mitochondria, and this regulation ensures the Ca^2+^ signaling from ER into mitochondria ([@ref37]). In addition, another Ca^2+^ channel, Ryanodine receptor (RyR), is also activated by Sigma-1 receptor agonists ([@ref116]).

Sigma-1 receptor is involved in the generation of reactive oxygen species (ROS). Its activation inhibits ROS generation in cells. ROS produced by NADPH oxidase is increased in neurons with reduced Sigma-1 receptor expression ([@ref85]). Further, ROS level is elevated in retinal Müller cells deficient in Sigma-1 receptor ([@ref123]). ROS production induced by lipopolysaccharide (LPS) was also reduced by Sigma-1 receptor agonist, (+)-pentazocine, in retinal microglia ([@ref133]). In contrast, in the spinal cord and brain mitochondria, Sigma-1 receptor agonists increase the production of ROS ([@ref17]; [@ref75]). These conflicting results regarding the effect of Sigma-1 agonists and antagonists on the ROS generation require further study.

It is proposed that the activation of Sigma-1 receptor modulates the antioxidant response elements; therefore, its agonists could be used as indirect antioxidants ([@ref85]). Inositol-requiring enzyme 1 (IRE1) is one of the ER stress sensors residing specifically at the MAM. Under ER stress, the Sigma-1 receptor was dissociated from BiP and its chaperone activity was activated, which stabilized IRE1 at the MAM, then the dimerization of IRE1 resulted in its activation. Once activated, IRE1 upregulated the transcription of several ER chaperones to counteract the ROS-induced stress on cells ([@ref70]; [@ref36]). Sigma-1 receptors also attenuate the production of ROS by enhancing the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway ([@ref123]).

Sigma Receptor Interactions With Proteins {#sec7}
-----------------------------------------

The Sigma-1 receptor is able to bind many proteins including ion channels such as inositol triphosphate (IP~3~) receptors ([@ref37]), voltage-gated K^+^ ([@ref55]), Na^+^ ([@ref50]), Ca^2+^ channels ([@ref117]), and NMDA receptors ([@ref83]). In addition, the Sigma-1 receptor could directly modulate neuronal mitochondrial Rac-1 GTPase activity ([@ref75]).

Binding immunoglobulin protein (BiP), also known as 78-kDa glucose-regulated protein (GRP78) or heat shock 70-kDa protein 5 (HSP5), is a protein located in the MAM as a molecular chaperone. Sigma-1 receptor interacts with BiP which is Ca^2+^-sensitive under physiological conditions ([@ref37]; [@ref81]). However, the decrease of the local Ca^2+^ concentration, or Sigma-1 receptor agonists, causes Sigma-1 receptor to dissociate from BiP, resulting in its redistribution from MAM to the ER and the increase of its chaperone activity ([@ref37]).

Sigma-1 receptors also interact with many GPCRs including opioid receptor, corticotropin-releasing factor (CRF) receptor, orexin receptor, and dopamine receptors ([@ref53]; [@ref77], [@ref78], [@ref79], [@ref76]; [@ref8]; [@ref25]). Although Sigma-1 receptor doesn't belong to the opioid receptor family, it physically associates with mu opioid receptor. This association was demonstrated by Co-IP experiments using epitope-tagged receptors in HEK293 cells. Sigma-1 receptors could modulate opioid function without changing its binding ([@ref53]).

In addition, bioluminescent resonance energy transfer-based technique (BRET) experiments showed that a direct interaction between Sigma-1 receptor and CRF1 receptor exists in HEK293 cells. CRF1 receptor participates in cocaine-dependent actions *via* Sigma-1 receptor -- CRF1 receptor oligomer ([@ref79]). Similarly, Sigma-1 receptor also binds CRF2 receptor physically, which mediates amphetamine effects on CRF2 receptor ([@ref76]).

Interestingly, although Orexin1 receptor is not able to physically interact with Sigma-1 receptor ([@ref79]), there is a direct interaction between Orexin-1 receptor and Sigma-2 receptor demonstrated by BRET assay, amphetamine affects Orexin1 receptor function *via* this binding ([@ref76]).

Sigma-1 receptor also binds dopamine receptor. Dopamine receptors consist of at least five subtypes (D1R, D2R, D3R, D4R, and D5R); D1-like receptors include D1R and D5R which stimulate adenylyl cyclase, while D2-like receptors include D2R, D3R, and D4R which inhibit adenylyl cyclase ([@ref7]). Using BRET, a direct interaction between Sigma-1 receptor and dopamine D1 receptor was reported in murine striatal slices ([@ref77]). A similar method was used to study the functional interaction between Sigma-1 receptor and dopamine D2-like receptor. It has demonstrated that only D2 receptor could physically interact with Sigma-1 receptors while D3 and D4 receptors did not in mouse striatum. Cocaine inhibited downstream signaling in both cultured cells and mouse striatum by interacting with Sigma-1 receptor -- D2 receptor complex ([@ref78]). This complex also exists in rat striatal dopaminergic and glutamatergic terminals ([@ref8]). In addition, the expression of this complex was reduced in rat alcohol drinking model ([@ref25]).

Sigma Receptor Ligands {#sec8}
----------------------

The Sigma-1 receptor shows high affinity for many unrelated and structurally diverse ligands ([Table 1](#tab1){ref-type="table"}). They include cocaine ([@ref55]), methamphetamine ([@ref38]), the antipsychotic drug haloperidol ([@ref129]), and antidepressants such as fluoxetine ([@ref98]). The actions of these drugs could be mediated by the Sigma-1 receptor.

###### 

The list of Sigma-1 receptor agonists and antagonists.

  Sigma receptor ligands -- agonists       Sigma receptor ligands -- antagonists
  ---------------------------------------- ---------------------------------------
  PD 144418                                BD 1063
  4-PPBP                                   BD 1047
  Pentazocine                              NE-100
  (+)-SKF 10,047                           BMY 14802
  PRE-084                                  Haloperidol
  Pregnenolone sulfate (PREGS)             
  Dehydroepiandrosterone sulfate (DHEAS)   
  SA 4503                                  
  Fluvoxamine                              
  DTG                                      
  SKF 83959                                
  MDMA                                     
  Memantine                                
  Phencyclidine                            
  Heroin                                   
  Cocaine                                  
  Methamphetamine                          
  Dehydroepiandrosterone (DHES)            
  SOMCL-668                                
  LS-1-137                                 

In order to explain this diversity, it was suggested that the Sigma-1 receptors possess flexible structures, which could bind all these structurally diverse compounds. In 2005, Glennon et al. proposed a model for pharmacophore for the Sigma-1 receptor ligands ([@ref30]). This pharmacophore includes a central basic amine nitrogen atom surrounded by two hydrophobic features. One feature is a primary hydrophobic group which is 6--10 Å away from the central nitrogen atom. The other one is a secondary hydrophobic group that is located 2.5--3.9 Å from the nitrogen atom. This feature could interact with the bulky substituent of ligands without affecting their binding affinity ([@ref30]).

Up to now, because of lack of a clear-cut methodology, we still don't understand the mechanism of this diverse ligand-receptor interaction. Recently, a new method was developed to address this dilemma. In this study, a Sigma-1 receptor biosensor consisting of CFP and YFP was constructed; when ligand bound to Sigma-1 receptor, it induced the receptor to rearrange its intramolecular conformation, which was monitored by real-time FRET-based assay. By this way, we could compare the intrinsic activity of different Sigma-1 receptor ligands. It has shown that Sigma-1 receptor agonists or antagonists induced conformation of Sigma-1 receptors to be rearranged in an opposite manner ([@ref31]).

The Physiological Roles of Sigma Receptor in the Central Nervous System {#sec9}
=======================================================================

Neuronal Excitability {#sec10}
---------------------

Through both indirect and direct physical interactions, the Sigma-1 receptor could modulate various ion channels including voltage-gated Ca^2+^, Na^+^, and K^+^ channels, which involve both action potential's generation and its conduction; by this way, the Sigma-1 receptor has the ability to affect cell excitability of the neuron ([@ref56]).

The Sigma-1 receptor could enhance or inhibit Ca^2+^ channel activity through either direct or indirect actions ([@ref56]). To date, only few studies have shown the direct action of Sigma-1 receptor on Ca^2+^ channels in the CNS ([@ref73]; [@ref132]). In cultured retinal ganglion cells, the activation of Sigma-1 receptor by [SKF10047](https://www.ncbi.nlm.nih.gov/protein/SKF10047) inhibited Ca^2+^ currents, and this effect was abolished by Sigma-1 receptor antagonist BD 1047. In addition, the association between the Sigma-1 receptor and Ca^2+^ channel was shown by Co-IP experiments ([@ref73]). N-type Ca^2+^ currents from cholinergic interneurons in rat striatum were also reduced by Sigma-1 receptor agonists (SKF-10047 and Pre-084) ([@ref132]), this inhibition was prevented by Sigma-1 receptor antagonist BD 1063. Sigma-1 receptors and N-type Ca^2+^ channels bind together, which is demonstrated by FRET assays and Co-IP ([@ref132]).

In contrast, Sigma-1 receptor activated by pregnenolone sulfate (PREGS) enhanced the activity of L-type Ca^2+^ channel and facilitated LTP induction in hippocampal slices, the involvement of Sigma-1 receptor demonstrated that Sigma-1 receptor antagonist BD 1047 prevented this PREGS induced facilitation. But, whether Sigma-1 receptor interacted with Ca^2+^ channels directly was not studied ([@ref96]).

For Na^+^ channel, the Sigma-1 receptor could inhibit its activity both directly and indirectly ([@ref16]; [@ref5]). In prefrontal cortex slice, the Sigma-1 receptor activated by dehydroepiandrosterone sulfate (DHEAS) inhibits Na^+^ current through Gαi protein and protein kinase C (PKC) pathway ([@ref16]). However, several other studies have shown that the Sigma-1 receptor can also modulate Na^+^ current directly through physical interaction ([@ref5]). In cardiomyocytes, Sigma-1 receptor ligands reduce Nav1.5-dependent currents; this reduction of Na^+^ current doesn't require the inclusion of ATP and GTP, indicating the direct action of Sigma-1 receptor on Na^+^ channels ([@ref50]). Atomic force microscopy (AFM) studies have revealed that Sigma-1 receptor directly binds Na^+^ channels with a four-fold symmetry ([@ref5]).

The regulation of K^+^ channels by Sigma-1 receptor involves either indirect mechanisms or direct protein--protein interactions; it could modulate K^+^ channels' function and trafficking ([@ref113]; [@ref56]). In cortical neurons, the Sigma ligands increase the Kv2.1-dependent current *via* Gi/o-dependent pathway ([@ref112]). To date, evidences for a direct physical interaction between Sigma-1 receptor and K^+^ channels also appear. The activation of the Sigma-1 receptor could differentially inhibit the Kv1.4 current, which suggests that the Sigma-1 receptor might act as a K^+^ channel subunit ([@ref4]). It is reported that the interaction between Sigma-1 receptor and Kv channels also occurs in the brain ([@ref55]). The activation of Sigma-1 receptor enhances the trafficking of Kv1.2 channels to the PM in both the nucleus accumbens (NAc) and the prefrontal cortex (PFC), which is proposed to be mediated by Sigma-1 receptor-Kv1.2 interaction. In addition, *in vivo* injection of cocaine increases Kv1.2 current in NAc neurons *via* this interaction ([@ref55]).

The effects of the Sigma-1 receptor on overall neuronal activity are brain region- and cell type-specific. Usually, the inhibition of Na^+^ channels by the Sigma-1 receptor ([@ref16]; [@ref5]) decreases action potential, whereas inhibition of K^+^ channels ([@ref4]; [@ref55]) increases it. Since Sigma-1 receptor activation has opposite effects on these voltage-dependent ion channels, it is impossible to infer its effects on the overall neuronal activity based on the combination of their diverse effects on these channels. Furthermore, ion channels involved in neuronal excitability have many subtypes, and Sigma-1 receptor might have opposite effects on these different subtypes, which make the role of Sigma-1 receptor on neuronal excitability more complicated. In conclusion, the overall effect of Sigma-1 receptor on neuronal activity may depend on both the expression level of Sigma-1 receptor and the subtypes of voltage-dependent ion channels.

Synaptic Plasticity, Learning and Memory {#sec11}
----------------------------------------

A well-accepted cellular model of learning and memory in the hippocampus is synaptic plasticity, including LTP and LTD; both forms are NMDA receptor (NMDAR) dependent ([@ref88]). So NMDAR is important for synaptic plasticity and learning and memory ([@ref88]).

It is demonstrated that Sigma-1 receptor ligands have the ability to regulate NMDAR activity bidirectionally. Sigma-1 receptor agonists increase NMDAR activity in many brain regions, including the CA3 field of rat dorsal hippocampus ([@ref96]; [@ref6]; [@ref84]). This potentiation of NMDAR by Sigma-1 receptor could be indirect through signaling pathways, and many studies have revealed that this enhancement maybe is mediated by inhibiting small-conductance K^+^-activated Ca^2+^ channels (SK channels) and/or through G proteins ([@ref96]). In addition, Sigma-1 receptor could regulate NMDAR directly by physical interaction. Using AFM and *in situ* proximity ligation assays (PLA), Balasuriya et al. discovered a direct association between Sigma-1 receptor and NMDAR. Sigma-1 receptor bound directly to the GluN1 subunit of NMDAR ([@ref6]). Furthermore, the activation of Sigma-1 receptor enhanced the trafficking and surface expression of NMDARs in the hippocampus ([@ref84]).

Additionally, Sigma-1 receptor could function as a safety switch to control cannabinoid receptor 1 (CB1R)-NMDAR interactions, rescuing CB1R-induced NMDAR hypofunction ([@ref94]). Sigma-1 receptors were found to form a complex consisting of CB1R, GluN1, and the histidine triad nucleotide-binding protein 1 (HINT1) ([@ref94]). The activation of Sigma-1 receptor could restore the hypofunctional NMDAR induced by CB1R ([@ref94]).

On the other hand, the activation of Sigma-1 receptor reduced NMDAR activity in rat cortical neurons ([@ref58]), retinal ganglion neurons ([@ref131]), and midbrain dopaminergic neurons ([@ref106]). The suppression of NMDAR function caused by the activation of Sigma-1 receptors is proposed to be mediated by a PLC-PKC pathway which is Ca^2+^-dependent ([@ref131]).

Although the modulation of NMDAR by Sigma-1 receptor has been well studied, the effect of Sigma receptor ligands on AMPAR is largely unknown. In rat retinal ganglion cells, Sigma-1 receptor ligands inhibit AMPAR activity; this inhibition is Ca^2+^ independent and PKG dependent, neither protein kinase A (PKA) nor phosphoinositide (PI)-phosphoinositide phospholipase C (PLC) pathways is involved ([@ref59]).Since Sigma-1 receptor has the ability to modulate both NMDARs and AMPARs, it is not surprising that Sigma-1 receptor could affect synaptic plasticity. LTP was reduced in Sigma-1 receptor knockout mice ([@ref110]). Additionally, in the hippocampus, the activation of Sigma-1 receptor increased LTP *via* the inhibition of SK channels ([@ref96]).

In addition to synaptic plasticity, a new hypothesis was proposed recently. It claimed that the dynamic balance of membrane receptor complexes at synapses is the molecular basis for learning and memory ([@ref12], [@ref13]). In this model, during short-term memory, learning can induce the transient reorganization of homo- and hetero-receptor complexes (made up of different receptors and adapter proteins including Sigma-1 receptors) in the postsynaptic membrane. This receptor reorganization then releases soluble factors like adenosine, ATP, growth factors, and ECVs from the postsynaptic membrane, which will reach the presynaptic membrane, resulting in the formation of a novel pattern of transmitter release ([@ref12], [@ref13]). Subsequently, the presynaptic hetero-receptor complexes are also reorganized to maintain this new pattern of transmitter release, which reflects the firing pattern to be learned by the complexes in the postsynaptic membrane ([@ref12], [@ref13]). For long-term memory, some hetero-receptor complexes in the postsynaptic membrane are converted into some unique transcription factors, which induce the synthesis of novel adaptor and scaffolding proteins. These new synthesized proteins then link these hetero-receptor complexes together or to the cytoskeleton, resulting in the formation of much more stable complexes. By this way, long-term memory is created ([@ref12], [@ref13]).

Many studies have demonstrated that Sigma-1 receptor is involved in learning and memory. For example, Sigma-1 receptor agonists enhance the learning and memory behaviors in mice ([@ref134]). Further, when memory was impaired by phencyclidine (PCP) in rat novel object recognition, it could be rescued by Sigma-1 receptor activated by pridopidine ([@ref99]). In another study, LS-1-137, a Sigma-1 receptor agonist, could partially reverse the learning deficits induced by scopolamine administration in learning and memory behavior tests; scopolamine is a muscarinic receptor antagonist ([@ref61]). Additionally, Ayahuasca, a psychoactive plant brew used for therapeutic and spiritual purposes, could heal traumatic memories *via* Sigma-1 receptor ([@ref45]).

Neuroprotection {#sec12}
---------------

### Modulation of Endoplasmic Reticulum Stress {#sec13}

When unfolded or misfolded proteins within the ER lumen are accumulated, they would activate three major signaling pathways to restore protein folding homeostasis; this is called the unfolded protein response (UPR), and these three major signaling pathways include protein kinase RNA-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol requiring enzyme 1 alpha (IRE1α) ([@ref39]; [@ref40]). The activation of UPR decreases the production of newly synthesized proteins and induces the degradation of misfolded proteins, which reduces the overload of the ER lumen by proteins. However, if the stress signal is severe and/or prolonged, it will result in cell death ([@ref39]; [@ref40]).

As chaperones, Sigma-1 receptors could degrade unfolded and/or misfolded proteins to reduce ER stress. Under normal conditions, Sigma-1 receptor interacts with another ER-chaperone BiP directly ([@ref113]). During ER stress Sigma-1 receptor dissociates from BiP and then binds and stabilizes IRE1a, which reliefs ER stress. In addition, ER stress could upregulate the expression of Sigma-1 receptor ([@ref69]). For example, the activation of Sigma-1 receptors by fluvoxamine increases Sigma-1 receptor expression, which inhibits the death of Neuro2A cells ([@ref80]).

### Modulation of Ca^2+^ Homeostasis and Glutamate Toxicity {#sec14}

The regulation of intracellular Ca^2+^ homeostasis is one of the major mechanisms by which Sigma-1 receptor ligands perform neuroprotection. High concentration of Ca^2+^ in the cytosol results in cell death. In addition to influx through NMDARs and voltage-dependent Ca^2+^ channels, Ca^2+^ can also be released from intracellular ER and mitochondria stores.

In the MAM, the interaction between Sigma-1 receptors and BiP is sensitive to Ca^2+^ change ([@ref37]); Ca^2+^ depletion causes the dissociation of this complex, resulting in the redistribution of the Sigma-1 receptor from MAM to the ER ([@ref37]). In addition, this interaction also stabilizes IP~3~R at the MAM, regulating Ca^2+^ influx into mitochondria and thus influencing ATP production *via* the activation of the Krebs' cycle ([@ref37]).

In the CNS, glutamate is the major excitatory neurotransmitter which could trigger the opening of NMDAR. Many studies have shown that hypofunctional NMDAR is detrimental to the neurons. The enhancement of NMDAR function by the activation of Sigma-1 receptor is beneficial under most situations. On the other hand, overactivated NMDAR is also not good for the neurons. When a large amount of Ca^2+^ flows into the cytosol *via* NMDARs, it activates downstream cell death pathways, including the activation of calpains and proteases ([@ref115]). Interestingly, under certain conditions, activation of Sigma-1 receptors could inhibit NMDAR activity ([@ref58]; [@ref106]; [@ref131]). This reduction of NMDAR function by Sigma-1 receptors might involve a Ca^2+^-dependent PLC-PKC pathway ([@ref131]). In addition to influencing the function of NMDARs, Sigma-1 receptor ligands also modulate glutamate release, although the mechanisms are poorly understood. In rat cerebral cortex, the application of Sigma-1 agonists reduced Ca^2+^ entry through the inhibition of presynaptic voltage-dependent Ca^2+^ channels, resulting in decreased glutamate release from nerve terminals ([@ref60]). In conclusion, through the modulation of glutamate release and NMDARs, Sigma-1 receptors may dampen the excitotoxic effect of glutamate.

Sigma-1 receptor ligands might also affect the interaction of NMDARs with other proteins to protect neurons from death. It is proposed that when there is excess Ca^2+^ influx through NMDAR, it activates nNOS within the NMDAR-PSD95-eNOS complex; thus, a large amount of NO is produced which contributes to neurotoxicity ([@ref100]). The activation of sigma-1 receptor could reduce the interactions between GluN2B and PSD95 as well as PSD95 and nNOS, protecting the neurons against cell death ([@ref127]). In addition, Sigma-1 receptor agonists also stimulated the binding of HINT1 to GPCRs which enhanced GPCR-NMDAR interactions; by this way, the activation of Sigma-1 receptor could protect the neurons against NMDAR-induced neurotoxicity ([@ref94]).

### Modulation of Neuroinflammation {#sec15}

Microglia are the primary innate immune effector cells in the CNS ([@ref41]; [@ref111]). Under normal conditions, microglia constantly sense the changes in their environment ([@ref35]). The ability of microglia to react to CNS damage underlies their importance in neurodegeneration ([@ref41]; [@ref111]). As a result of disruptions in CNS homeostasis, brain injury or other perturbations, microglia are activated and release pro-inflammatory mediators including cytokines and ROS, which result in neuronal death ([@ref41]; [@ref111]).

Similar to macrophages, microglia usually have two phenotypes: M1 and/or M2 phenotypes. M1 microglia are pro-inflammatory and their activation is harmful to the CNS, while M2 microglia are anti-inflammatory and protective ([@ref41]; [@ref111]). Sigma-1 receptors, also expressed in microglia, might modulate microglial activation and dampen neuroinflammation ([@ref49]). Sigma-1 receptors regulate several aspects of microglial activation. In rat microglial cultures, the Sigma-1 receptor agonist DTG reduces the ability of microglia to release TNF-α, IL-10, and NO in response to ATP, MCP-1, and LPS ([@ref133]). In addition, in murine microglial BV2 cells, the activation of the Sigma-1 receptor prevented M1 microglial activation induced by LPS and decreased the release of inflammatory cytokines ([@ref125]).

In contrast, in animals with motor neuron disease, the application of PRE084 increased M2 microglial phenotypes ([@ref90]). Sigma ligands improved microglial cell survival during ischemia or Aβ exposure in primary microglia cultures ([@ref9]). In conclusion, the activation of Sigma receptors may modulate microglial activity by enhancing its anti-inflammatory M2 phenotype while reducing its inflammatory response (M1).

In addition to microglia, astrocyte is also involved in neuroinflammation. Depending on the properties of injuries, when astrocytes are activated, they could release gliotransmitters, pro-inflammatory cytokines, and neuroprotective factors such as BDNF. Sigma-1 receptor is highly expressed in astrocytes, indicating its ability to modulate the functions of astrocytes. In cultured astrocytes, haloperidol induced GM1 accumulation in the autophagosomes of astrocytes *via* the activation of Sigma-1 receptor ([@ref51]). GM1 is a sialic acid-containing glycosphingolipid, which is highly abundant in the CNS; it is involved in neuroinflammation ([@ref102]). Furthermore, in a mouse model of motor neuron degeneration (MND), the activation of Sigma-1 receptor by PRE-084 decreased reactive astrocytosis ([@ref90]). In addition, using neuronal-glial mixed cultures, GFAP expression was enhanced in Sigma-1 knockout mice compared to that of WT ([@ref124]).

The Role of Sigma Receptor in Parkinson's Disease and Major Depressive Disorder {#sec16}
===============================================================================

Parkinson's Disease {#sec17}
-------------------

Parkinson's disease (PD) is a common neurodegenerative disorder demonstrated by the massive death of dopaminergic neurons in substantia nigra pars compacta (SNpc) and the existence of Lewy bodies, which consist of α-synuclein ([@ref91]). Its classical motor features include bradykinesia, rest tremor, and muscle rigidity ([@ref91]). PD also has some non-motor symptoms such as memory impairment, sleep disorders, depression, and autonomic dysfunction, which affect the quality of patients' life ([@ref15]). The etiology of sporadic PD remains to be unraveled, but it involves genetic, lifestyle, and environmental factors ([@ref91]).

Many penetrant genes associated with PD have been identified including α-synuclein, DJ-1, LRRK-2 (which encodes leucine-rich repeat kinase 2), and GBA (which encodes glucocerebrosidase) ([@ref91]). Mutations of these genes can cause abnormal α-synuclein proteostasis, mitochondrial dysfunction, oxidative stress, neuroinflammation, and motor circuit pathophysiology ([@ref91]). Oxidative stress is a potential driver for PD progression. The accumulation of oxidative damage markers in the substantia nigra has been demonstrated in brain tissues from patients with PD ([@ref48]). Oxidative stress may accelerate α-synuclein aggregation ([@ref20]) and cell death ([@ref34]). Sigma-1 receptor agonists were found to reduce oxidative stress *via* several signaling pathways ([@ref85]; [@ref123]), indicating the beneficial role of Sigma-1 receptor in PD.

In addition, the Sigma-1 receptor binds cocaine and methamphetamine and gets involved in their behavioral and cellular effects on animals ([@ref55]; [@ref38]). One study has demonstrated that Sigma-1 receptors are involved in dopamine (DA)-induced cell death in CHO cells ([@ref71]). In CHO cells deficient in Sigma-1 receptor, physiological concentration of DA induced cell death. It is proposed that nuclear factor κB (NF-κB) p105 is converted to p50 by DA, which reduces the transcription of Bcl-2 ([@ref71]). Therefore, endogenous Sigma-1 receptors could tonically inhibit DA-induced NF-κB activation, which protects cell from death. Thus, Sigma-1 receptor ligands may represent new therapeutic targets for PD.

In early stage PD patients, the level of Sigma-1 receptors is downregulated ([@ref67]). In addition, [@ref28] treated 6-hydroxydopamine (OHDA) model mice with the Sigma-1 receptor agonist PRE-084 daily; after 5 weeks, these PD model mice exhibited a significant behavioral recovery ([@ref28]). [@ref44] reported that in Sigma-1 KO mice, the death of dopaminergic neurons increased. This phenomenon was caused by the aggregation and phosphorylation of α-synuclein ([@ref44]). Whereas in 2015, the same group reported inconsistent results using the 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) model mice. The authors found that deficiency of Sigma-1 receptor could reduce MPTP-induced death of dopaminergic neurons, which is mediated by the suppression of NMDAR function and DA transporter expression ([@ref43]). These contradictory observations can be reconciled because they used different animal models. While MPTP is a mitochondrial toxicant, it may directly impact mitochondrial functions.

Recently, PD circuit dysfunction has attracted more and more attention. It likely represents a new direction for the treatment of PD ([@ref65]). The basal ganglia which control the movement of body are the major brain areas affected in PD. They consist of several nuclei including the caudate nucleus, the putamen, the substantia nigra, and the globus pallidus. These nuclei form an interconnecting network which processes the signals for initiation and termination of movement ([@ref65]). The death of dopaminergic neurons in substantia nigra pars compacta could induce dysregulation of the motor circuits that project throughout the basal ganglia ([@ref65]). Up to now, whether Sigma-1 receptor is involved in basal ganglia circuit function remains unknown.

Major Depressive Disease (MDD) {#sec18}
------------------------------

Major depressive disorder (MDD) is a debilitating disease with depressed mood and poor cognitive function ([@ref82]). It is caused by both heritability and environmental factors. Environmental factors, including physical or emotional abuse during early life, are strongly linked to MDD ([@ref82]). MDD is linked to the dysfunctions of dopaminergic, serotonergic, and glutamatergic systems ([@ref82]). For example, it is very common to use selective serotonin reuptake inhibitor (SSRI) to treat depression; this inhibitor can block serotonin reuptake in the synaptic cleft, thus increasing the concentration of serotonin ([@ref27]). In addition, early life stress could induce depression by changing serotonin levels in the brain ([@ref52]). Some SSRIs also act on dopaminergic system to exert their antidepressant effects ([@ref92]). Studies have shown that low level of dopamine is linked to MDD ([@ref10]). Additionally, the application of dopamine agonists can rescue the symptoms of depression ([@ref57]). Recently, it has been shown that abnormal function of glutamatergic system also leads to MDD ([@ref74]). A strong evidence which supported this hypothesis is that the NMDAR blocker ketamine has the ability to rescue the core symptoms of depression ([@ref128]). Furthermore, postmortem studies showed that in MDD patients, the expression and function of NMDAR subunits were altered ([@ref26]).

Up to now, the first generation of antidepressants, SSRIs, has not helped approximately a third of patients with MDD. In addition, it usually takes several weeks to months for SSRIs to partially relieve the symptoms of MDD ([@ref74]). Although the monoamine systems (including the serotonin and dopamine systems) have been focused by depression research, now more and more researchers agree that the other targets should be pursued ([@ref74]). Recently, Sigma receptors have emerged as a promising target.

Polymorphisms and association analyses have suggested that Sigma-1 receptor is involved in MDD. A genetic link between Sigma-1 receptor and MDD was discovered in a Japanese population ([@ref54]). In addition, Sigma-1 receptor knockout mouse demonstrated increased depressive-like phenotype ([@ref97]). Mounting pharmacological data have suggested that many Sigma-1 receptor agonists play very important antidepressant roles ([@ref62]; [@ref122]). One study has shown that Sigma receptor agonists reduce depression ([@ref62]; [@ref119]; [@ref122]). Moreover, the application of SOMCL-668, which could modulate Sigma-1 receptor activity, decreased depressive-like behaviors in mice ([@ref121]). Furthermore, antidepressant actions of the neurosteroids DHEAS and pregnenolone sulfate (PS) appear to be mediated by Sigma-1 receptors ([@ref93]; [@ref120]). Antidepressant actions of several other compounds, including fluvoxamine, were prevented by Sigma-1 receptor antagonist ([@ref122]; [@ref22]).

The mechanism by which Sigma-1 receptors modulate antidepressant-like behavior is not understood. It is proposed that the modulation of serotonergic transmission may be involved since Sigma-1 receptor knockout mice with the increased depressive-like behavior also showed deficits in the activity of serotonergic neurons ([@ref97]). Electrophysiological studies demonstrated that Sigma receptor agonists increase the activity of serotonergic neurons in the dorsal raphe nucleus ([@ref11]). Furthermore, when DTG or SA-4503 (two Sigma-1 receptor agonists) was combined with 8-OH-DPAT, a 5-HT1A receptor agonist, there was an enhanced antidepressant action in rats ([@ref109]).

In addition, Sigma-1 receptor modulates the dopaminergic neurotransmission as well. Sigma-1 receptors and dopaminergic neurotransmission are strongly related. The application of Sigma-1 receptor ligands enhances both the spontaneous and the NMDA-induced neuronal activity of dopaminergic neurons in the rat mesolimbic and nigrostriatal dopaminergic systems ([@ref33]). Furthermore, the activation of Sigma-1 receptor increases the concentration of extracellular dopamine in both the hippocampus and the frontal cortex ([@ref66]; [@ref22]). Similarly, the antidepressant activity of ropinirole which is a D2/D3 dopamine receptor ligand is mediated by Sigma receptors ([@ref22]). All these results indicate that the Sigma receptor ligands have ability to modulate the dopaminergic system in the brain.

It has been found that Sigma-1 receptor agonists also affect glutamatergic neurotransmission. They could potentiate the effect of NMDAR antagonists. For example, SA-4503 enhanced the antidepressant activity of amantadine and memantine (they are all NMDA receptor antagonists) in rat ([@ref107], [@ref108]). In addition, dehydroepiandrosterone (DHES) exerts antidepressant effects in rat prelimbic cortex *via* the enhancement of glutamate release ([@ref23]).

Additionally, Sigma-1 receptor might exhibit antidepressant-like behaviors *via* its modulation on neurogenesis. In the subgranular zone of the dentate granule (DG) of olfactory bulbectomized mice (OBX mice), the application of Dehydroepiandrosterone (DHEA) significantly increases neurogenesis through the activation of the Akt/GSK3β-catenin pathway ([@ref72]). Also, in Sigma-1 receptor knockout mice, neurogenesis in DG was significantly impaired, which was proposed to contribute to its depressive behaviors ([@ref105]).

MDD and PD are closely related. As mentioned above, depression is an early non-motor symptom in PD; it appears before the onset of motor symptoms ([@ref91]). Interestingly, depression is also a risk factor for PD. Patients with depression have high risk of developing PD when they grow old ([@ref29]). In addition, hypothalamic--pituitary--adrenal (HPA) axis which is involved in depression plays an important role in the development of PD ([@ref24]). An antidepressant, fluvoxamine maleate which is used to treat MDD, also showed benefits for PD treatment ([@ref21]). Since Sigma-1 receptor is involved in both PD and MDD, whether it is the link between these two diseases needs further clarification.

Concluding Remarks {#sec19}
==================

Sigma receptors have been involved in many physiological and pathological processes. They are directly associated with GPCRs, ion channels, and other proteins, acting as a scaffolding protein. Although the important roles of Sigma receptors in PD and MDD have been well revealed, several questions still remain, including: (1) What is the structural basis for Sigma-1 receptors to bind their diverse ligands? (2) Since Sigma-1 receptor could form a range of different types of oligomers, what are the roles of these different oligomers? In addition, Sigma-1 receptor agonists appear to favor low oligomeric states, while its antagonists favor high oligomeric states. Do different agonists and antagonists of Sigma-1 receptor induce distinct cellular effects through these distinct oligomeric states? (3) Sigma receptors interact with so many proteins. How do we design the drug to target the specific disease-related proteins without affecting other interacting proteins? (4) What is the molecular identity of Sigma-2 receptor? (5) The role of the Sigma-2 receptor is still poorly understood, future studies are needed. (6) Although many current medications in the market for MDD show significant affinity for Sigma-1 receptors, whether they act through Sigma-1 receptors in humans remains unanswered. (7) Although Sigma receptors have been demonstrated to be involved in PD and MDD, the mechanisms how dysfunctional Sigma receptors contribute to these diseases require further study.
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